

NEUROVASCULAR DYSFUNCTION BIOCHIP

EARLY DIAGNOSIS CAN MAKE A DIFFERENCE



Powered by Biochip Array Technology

Biochip enables rapid and precise multianalyte detection from a single patient sample, utilising a biomarker algorithm to offer a highly sensitive screen to stratify neurovascular dysfunction.



Biochip enables clinicians to accurately identify stroke, classify stroke subtypes, triage, and intervene immediately.



Biochip monitors patient response to treatment in real-time, enabling faster tailored clinical intervention.




Biochip improves patient outcomes through rapid targeted treatment plans



Biochip could save UK hospitals over £500 million/ year through shorter ICU stays, efficient resource use, and fewer complications and readmissions

Data-Driven Risk Stratification

The Neurovascular Dysfunction Biochip provides clinicians with rapid quantitative results of 8 key biomarkers, facilitating fast and accurate classification of neurovascular dysfunction in an ICU setting.



Biomarkers

Glutathione S-transferase Pi (GSTPi)	Glial Fibrillary Acidic Protein (GFAP)	Soluble Tumour Necrosis Factor Receptor 1 (sTNFR1)
Parkinson Disease Protein 7 (PARK7)	Fatty Acid Binding Protein 3 (FABP3)	D-Dimer
Nucleoside Diphosphate Kinase A (NDKA)	Interleukin-6 (IL-6)	-

Product Information



Sample Type Plasma



Samples Per Cartridge 2



 $\begin{array}{c} \textbf{Sample Volume} \\ 400 \mu I \end{array}$



Result Type Quantitative



Time to Result 39 Minutes